Test filters

News

In the media

Press releases

Publications

Scientific articles

Statements

Stories

Videos

Viewpoints

Scientific articles

27 Feb 2026

Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review

PLOS Neglected Tropical Diseases

Scientific articles

18 Feb 2026

An MRC-5 cell based high-throughput, high-content imaging assay to identify hits against Trypanosoma cruzi intracellular parasites

SLAS Discovery

Press releases

4 Mar 2026

Pandemic preparedness: Novo Nordisk Foundation renews its support to DNDi and THSTI to continue the development of broad-spectrum antivirals

In the media

3 Mar 2026

Traitement à dose unique approuvé pour la maladie du sommeil

Nature Africa

In the media

3 Mar 2026

Single-dose treatment approved for sleeping sickness

Nature Africa

In the media

2 Mar 2026

Europa da el visto bueno a una terapia más sencilla contra la enfermedad del sueño

La Razon

In the media

27 Feb 2026

After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review’

Fierce Pharma

In the media

27 Feb 2026

EMA gives positive opinion for single-dose sleeping sickness medication

Citizen Digital

In the media

27 Feb 2026

Single-dose sleeping sickness pill clears major EU regulatory milestone

Capital FM

Press Releases Translations

27 Feb 2026

L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif de l’Agence Européenne des Médicaments (EMA) en tant que traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil

Press releases

27 Feb 2026

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

In the media

27 Feb 2026

Breakthrough single-dose treatment for sleeping sickness gets EU nod

KBC

In the media

27 Feb 2026

New sleeping sickness pill gets nod, paving the way for use in Africa

Associated Press

Scientific articles

27 Feb 2026

Evaluation of drug–drug interaction potential between the oral antibiotic zoliflodacin and the CYP3A4 inhibitor itraconazole: A phase 1 study in healthy participants

Clinical and Translational Science

In the media

27 Feb 2026

New pill has potential to eliminate deadly sleeping sickness

Bloomberg

In the media

27 Feb 2026

Maladie du sommeil : l’autorisation européenne d’un nouveau traitement laisse entrevoir une élimination de la maladie d’ici à 2030

Le Monde

International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review

An MRC-5 cell based high-throughput, high-content imaging assay to identify hits against Trypanosoma cruzi intracellular parasites

Pandemic preparedness: Novo Nordisk Foundation renews its support to DNDi and THSTI to continue the development of broad-spectrum antivirals

Traitement à dose unique approuvé pour la maladie du sommeil

Single-dose treatment approved for sleeping sickness

Europa da el visto bueno a una terapia más sencilla contra la enfermedad del sueño

After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review’

EMA gives positive opinion for single-dose sleeping sickness medication

Single-dose sleeping sickness pill clears major EU regulatory milestone

L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif de l’Agence Européenne des Médicaments (EMA) en tant que traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Breakthrough single-dose treatment for sleeping sickness gets EU nod

New sleeping sickness pill gets nod, paving the way for use in Africa

Evaluation of drug–drug interaction potential between the oral antibiotic zoliflodacin and the CYP3A4 inhibitor itraconazole: A phase 1 study in healthy participants

New pill has potential to eliminate deadly sleeping sickness

Maladie du sommeil : l’autorisation européenne d’un nouveau traitement laisse entrevoir une élimination de la maladie d’ici à 2030

Learn more

Get in touch

Support us

Work with us